Drug Trial Radar · NCT03931317
Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity
Last checked: Nov 20, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Dec 3, 2018
Primary completion
May 20, 2021
Study completion Mar 1, 2023
Sponsor
- Lead sponsor
- University of California, San DiegoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bausch & Lomb Incorporated
- First posted
- Apr 30, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this research study is to compare the effect of Latanoprostene Bunod and Timolol on eye pressure and blood vessels of the back of the eye.
Conditions
- OAG - Open-Angle Glaucoma
- OHT - Ocular Hypertension
Interventions
Latanoprostene bunod 0.024% QDDrug
This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
Timolol maleate 0.5% BIDDrug
This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
Primary outcomes
What the sponsor says the trial is designed to measure.
- retinal blood vessel density (peripapillary and macular)Time frame: Through study completion, an average of 11 to 19 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UCSD Shiley Eye Institute
La Jolla, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.